Timothy Yap

The University of Texas MD Anderson Cancer Center

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (23)

Janos Roszik

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Kanwal Raghav

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Scott Tykodi

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

Michael Sawyer

Professor

University of Alberta

CANADA

View details

Anand Singh

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Aung Naing

UNITED STATES

View details

Niharika Mettu

Duke University

UNITED STATES

View details

Alexander Drilon

Thomas Jefferson University Hospital

UNITED STATES

View details

Apostolia M. Tsimberidou

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jonathan W. Goldman

Associate Professor

UCLA

UNITED STATES

View details

Gerald Falchook

UNITED STATES

View details

Paula Pohlmann

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Natalia Baran

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ruitao Lin

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Justin Moyers

UNITED STATES

View details

Sarina Piha-Paul

Associate Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Siqing Fu

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Ruth Plummer

Clinical Professor

Newcastle University

UNITED KINGDOM

View details

David S. Hong

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Robert G. Maki

Professor, Member

UNITED STATES

View details

Natalie Vokes

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Funda Meric-Bernstam

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Mohamed Gouda

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Timothy Yap

Research Interests

Explore related searches

Contact this professor

Articles (27)

A First-in-Human Study of ATM Inhibitor Lartesertib as Monotherapy in Patients with Advanced Solid Tumors

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

The DNA-PK inhibitor AZD7648 alone or combined with pegylated liposomal doxorubicin in patients with advanced cancer: results of a first-in-human Phase I/IIa study

Phase Ib Basket Expansion Trial and Alternative-Schedule Dose-Escalation Study of ATR Inhibitor Elimusertib in Advanced Solid Tumors with DNA Damage Response Defects

First-in-Human Phase I/IIa Study of the First-in-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer

Human Epidermal Growth Factor Receptor 2 Loss following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer

Intratumoral or Subcutaneous MK-2118, a Noncyclic Dinucleotide STING Agonist, with or without Pembrolizumab, for Advanced or Metastatic Solid Tumors or Lymphomas

Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations

Synthetic lethal strategies for the development of cancer therapeutics

First-in-Human Study of the Ataxia Telangiectasia and Rad3-Related (ATR) Inhibitor Tuvusertib (M1774) as Monotherapy in Patients with Solid Tumors

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

PIKing up and AKTing on Resistance Mutations in Osimertinib-Treated EGFR-Mutated NSCLC

PF-06952229, a selective TGF-β-R1 inhibitor: preclinical development and a first-in-human, phase I, dose-escalation study in advanced solid tumors

Pharmacodynamic Activity of [18F]-Fluorthanatrace Poly(ADP-ribose) Polymerase Positron Emission Tomography in Patients With BRCA1/2-Mutated Breast Cancer Receiving Talazoparib

Poly(ADP-Ribose) Polymerase Inhibitor Development: Promising Strategies to Move Beyond Approved Indications

Targeting ATR in patients with cancer

First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies

Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia

PARP inhibitors: enhancing efficacy through rational combinations

SHP2 Inhibition Sensitizes Diverse Oncogene-Addicted Solid Tumors to Re-treatment with Targeted Therapy

Aligning Germline Cancer Predisposition With Tumor-Based Next-Generation Sequencing for Modern Oncology Diagnosis, Interception, and Therapeutic Development

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies

A Phase 1 First-in-Human Study of FS118, a Tetravalent Bispecific Antibody Targeting LAG-3 and PD-L1 in Patients with Advanced Cancer and PD-L1 Resistance

Antibody-drug conjugates in lung cancer: dawn of a new era?

First-in-Human Phase I/II ICONIC Trial of the ICOS Agonist Vopratelimab Alone and with Nivolumab: ICOS-High CD4 T-Cell Populations and Predictors of Response

Collaborators (23)

Janos Roszik

Kanwal Raghav

Scott Tykodi

Michael Sawyer

Anand Singh

Aung Naing

Niharika Mettu

Alexander Drilon

Apostolia M. Tsimberidou

Jonathan W. Goldman

Gerald Falchook

Paula Pohlmann

Natalia Baran

Ruitao Lin

Justin Moyers

Sarina Piha-Paul

Siqing Fu

Ruth Plummer

David S. Hong

Robert G. Maki

Natalie Vokes

Funda Meric-Bernstam

Mohamed Gouda

Make your next move.